We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Christian
Ottensmeier
C.Ottensmeier@liverpool.ac.uk
Ben
Johnson
ben.johnson@liverpool.ac.uk
Dr
Serena
Chee
Serena.chee@uhs.nhs.uk
Serena
Chee
Serena.Chee@liverpool.ac.uk
Other bacterial diseasesInfluenza and pneumoniaMalignant neoplasms of lip, oral cavity and pharynxMalignant neoplasms of respiratory and intrathoracic organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The strength of the immune system or “Immunocompetence” is very important in the outcome of patients with cancer and infectious diseases. However, measuring immunocompetence is challenging as the immune system is very complex.
Patients with cancer and who are undergoing cancer treatments are known to be at higher risk of developing infections and also are less protected by vaccinations against infection. Many newer anti-cancer treatments such as immunotherapy and cancer vaccines aim to stimulate the immune system to fight against cancer. However, if the immune system is not working properly, these treatments may be less effective.
This study aims to develop a way to measure the strength of the immune system in patients with cancer to help improve vaccination strategies and to develop tools to predict responses to cancer treatment and prognosis. This study could also help develop new treatment strategies for patients, such as using vaccines in the treatment of patients with cancer.
Patients with lung or head and neck cancer who may benefit from vaccination against infections such as tetanus and flu will be invited to take part in the study.
Participants will have a blood sample taken before vaccination and up to 8 times after vaccination over the course of just over a year if possible. If surgery or a biopsy is part of the planned treatment, a sample of the tissue will also be collected. A number of people will be asked to have a skin challenge test and a small skin biopsy after vaccination against tetanus to understand how the immune system remembers the vaccination.
The study will be conducted in several hospital and hospice sites in the region of Liverpool and is funded by the National Institute of Health/National Institute of Allergy and Infectious Diseases Grant R24 AI108564-05.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patient deemed medically unfit for sample collection Patients with known or suspected immunodeficiencies (i.e HIV or other) Patient who received with immune-suppressing medications within the last two weeks of vaccination/initial blood sampling, oral dosing of > 10 mg/day prednisolone or equivalent or other immunosuppressive therapy for more than 14 days in the last 1 month prior to vaccination Patient with a contraindication for study procedures or sampling The absence/withdrawal of consent Previous severe hypersensitivity reaction to vaccination Patients with known egg allergy (influenza vaccination) or known allergy to other excipients of the vaccine Asplenic patients Pregnancy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Christian
Ottensmeier
C.Ottensmeier@liverpool.ac.uk
Ben
Johnson
ben.johnson@liverpool.ac.uk
Dr
Serena
Chee
Serena.chee@uhs.nhs.uk
Serena
Chee
Serena.Chee@liverpool.ac.uk
The study is sponsored by THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST and funded by National Institutes of Health (NIH), United States .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54443
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
